Previous Close | 9.58 |
Open | 9.58 |
Bid | 10.30 x 1100 |
Ask | 10.85 x 900 |
Day's Range | 9.58 - 10.88 |
52 Week Range | 2.82 - 40.00 |
Volume | 284,207 |
Avg. Volume | 306,092 |
Market Cap | 46.963M |
Beta (5Y Monthly) | 1.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.39 |
Earnings Date | Nov 10, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.81 |
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary financial and operational results for the fourth quarter and fiscal year ended December 31, 2020. In particular, Myomo expects revenue for the three months ended December 31, 2020 to more than double compared with the fourth quarter ended December 31, 2019, and also expects quarterly cash utilization to be the lowest since it became a publicly traded company in June 2017.
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, the Company’s chief executive officer, and David Henry, chief financial officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021. The presentation can be accessed at the following link and on the Investor Relations section of the Myomo website beginning on January 11, 2021 at 6:00 a.m. Eastern time and will be archived for 90 days.
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.